Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2022.6330 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Paula Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Columbia University School of Medicine, New York, New York. Hauptthemen laut MEDLINE: Acro-Osteolysis, Scleroderma, Systemic, Calcinosis, Vascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Degos-like lesions are cutaneous manifestations of a small-vessel vasculopathy that appear as atrophic, porcelain-white papules with red, telangiectatic borders. No study has adequately examined Degos-like lesions in patients with systemic sclerosis (SSc).
Objective
To characterize the serologic, cutaneous, and internal organ manifestations associated with Degos-like lesions in a large cohort of patients with SSc. Design, Settings, and Participants This retrospective cohort study involved adult patients with SSc who were seen at Stanford Rheumatologic Dermatology Clinic between January 1, 1998, and December 31, 2018. Participants fulfilled the 2013 classification criteria for SSc. Data analysis was conducted from February 1 to June 1, 2019. Main Outcomes and Measures Data on demographic characteristics; autoantibody status; clinical characteristics, including cutaneous and systemic manifestations of SSc; and presence of Degos-like lesions were collected.
Results
The cohort comprised 506 patients with SSc (447 females [88.3%]; mean [SD] age at first non–Raynaud disease symptoms, 46.1 [15.2] years). Twenty-seven patients (5.3%) had Degos-like lesions, of whom 24 (89.0%) had lesions affecting the fingers. Patients with Degos-like lesions were more likely to have diffuse cutaneous SSc compared with patients without lesions (15 [55.6%] vs 181 [37.8%]; P = .04). Degos-like lesions were also associated with acro-osteolysis (10 [37.0%] vs 62 [12.9%]; P < .01), digital ulcers (15 [55.6%] vs 173 [36.1%]; P = .04), and calcinosis (15 [55.6%] vs 115 [24.0%]; P < .01). While Degos-like lesions were not associated with internal organ manifestations, such as scleroderma renal crisis, interstitial lung disease, or pulmonary arterial hypertension, there was P < .10 for the association with gastric antral vascular ectasia. Conclusions and Relevance Results of this study suggest an association of Degos-like lesions with diffuse cutaneous SSc and other cutaneous manifestations of vasculopathy, including acro-osteolysis, calcinosis, and digital ulcers. A prospective longitudinal study is warranted to examine the onset of Degos-like lesions and to elucidate whether these lesions play a role in SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Rheumatology, Columbia University School of Medicine, New York, New York.
- Department of Dermatology, Stanford University School of Medicine, Palo Alto, California.
- Department of Urology, Stanford University School of Medicine, Palo Alto, California.
- Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California.
- Division of Immunology and Rheumatology, Palo Alto Veterans Affairs Healthcare System, Palo Alto, California.
Zitieren
APA
Song, P., Li, S., Lewis, M. A., Fiorentino, D. F., & Chung, L. (2023). Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.6330
Vancouver
Song P, Li S, Lewis MA, Fiorentino DF, Chung L. Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2022.6330
BibTeX
@article{Song2023,
author = {Song, Paula and Li, Shufeng and Lewis, Matthew A and Fiorentino, David F and Chung, Lorinda},
title = {Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2022.6330}
}
EUVIMED